Most general reagents used in this study were sourced from Sigma-Aldrich. The
siRNA oligonucleotides were purchased from Dharmacon. Primary antibodies used in this study were as follows: anti-TBC1D5 [Santa Cruz, sc-376296, dilution 1:400 or 1:1000 for immunofluorescence (IF) microscopy or western blotting (WB), respectively],
anti-VPS26 (Abcam, ab23892, 1:800 IF or 1:1000 WB),
anti-VPS35 [Santa Cruz,
sc-374372, 1:800 IF or 1:1000 WB, or from the Seaman lab (see Seaman, 2007 (
link)), 1:300 for IF], anti-CIMPR (Abcam,
ab2733, 1:400 IF or 1:1000 WB),
anti-Lamp1 (Santa Cruz, sc-18821, 1:500 IF or 1:1000 WB),
anti-Glut1 (Abcam, ab15309, 1:400 IF),
anti-GM130 (BD Transduction labs 610822, 1:500 IF), anti-Fam21 (Millipore, ABT79, 1:400 IF or 1:1000 WB),
anti-Aβ (Covance, SIG-39320, 1:1000 WB), anti-sAPPβ (IBL America, 10321, 1:800 WB), anti-Rab7a:GTP (NewEast Biosciences, 26923, 1:300 IF), anti-TGN46 (Seaman lab, see Seaman, 2007 (
link), dilution 1:600 IF),
anti-GFP (Seaman lab, see Seaman et al., 2009 (
link), 1:1000 for immunoprecipitation),
anti-Snx1 (BD Transduction labs, dilution 1:400 IF or 1:1000 WB) and
anti-Tubulin (Sigma-Aldrich, dilution 1:1000 WB). Secondary fluorescently labelled antibodies were purchased from Invitrogen.
Seaman M.N., Mukadam A.S, & Breusegem S.Y. (2018). Inhibition of TBC1D5 activates Rab7a and can enhance the function of the retromer cargo-selective complex. Journal of Cell Science, 131(12), jcs217398.